Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/14/2018 09/17/2018 09/18/2018 09/19/2018 09/20/2018 Date
188.22(c) 184.29(c) 186.07(c) 188.03(c) 192.51(c) Last
1 684 690 2 223 719 2 379 687 1 883 248 2 332 950 Volume
-0.98% -2.09% +0.97% +1.05% +2.38% Change
More quotes
Financials (USD)
Sales 2018 15 533 M
EBIT 2018 7 411 M
Net income 2018 -1 106 M
Debt 2018 23 063 M
Yield 2018 1,47%
Sales 2019 15 619 M
EBIT 2019 7 435 M
Net income 2019 -273 M
Debt 2019 19 930 M
Yield 2019 1,48%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 5,59x
EV / Sales2019 5,36x
Capitalization 63 826 M
More Financials
Company
Allergan Plc engages in the research, development, and manufacture of pharmaceutical products.It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International.The US Specialized Therapeutics segment includes sales and expenses relating to... 
Sector
Pharmaceuticals
Calendar
10/31Earnings Release
More about the company
Surperformance© ratings of Allergan plc
Trading Rating : Investor Rating :
More Ratings
Latest news on ALLERGAN PLC
09/20ALLERGAN : to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics..
AQ
09/20ALLERGAN : Unveils Spotlyte™, A First-In-Category Digital Hub Designed To ..
AQ
09/20ALLERGAN : to Host Medical Aesthetics Day Event on September 14, 2018
AQ
09/20ALLERGAN : Study Results from Allergan Update Understanding of Acute Kidney Inju..
AQ
09/20ALLERGAN : Teams Up with Actor Scott Eastwood to Encourage Recognition of World ..
PR
09/20ALLERGAN : Announces Results of Higher Dose BOTOX Cosmetic (onabotulinumtoxinA) ..
AQ
09/19ALLERGAN : Announces Plans to Build First Medical Aesthetics Innovation Center i..
PU
09/19ALLERGAN : Announces Results of Higher Dose BOTOX Cosmetic for the Treatment of ..
AQ
09/19ALLERGAN : Highlights Key Growth Drivers for Medical Aesthetics
AQ
09/19SOSEI : Allergan to delay trials of dementia candidate
AQ
More news
Sector news : Pharmaceuticals - NEC
09/20Animal health firm Elanco surges 41 percent on debut
RE
09/20WALL STREET STOCK EXCHANGE : Aurora Cannabis plans U.S. stock listing in October
RE
09/20ELI LILLY AND : Lilly Spinoff Elanco Animal Health Surges Early in Market Debut ..
DJ
09/20ONCOMED PHARMACEUTICALS : Says Celgene Won't Exercise Option to License Navicixi..
DJ
09/20PFIZER : 20vPnC Vaccine Gets FDA Breakthrough-Therapy Designation
DJ
More sector news : Pharmaceuticals - NEC
Latest Tweets
03:28a$AGN repeat Sweeper activity today, could roll out some of their recent buyin..
2
02:08a$AGN N.V. Morningstar | AGN Updated Forecasts and Estimates from 20 Sep 2018.. 
01:03a$AGNN plc Allergan Posts Impressive 2Q While Awaiting Generic Restasis; Shar.. 
12:12aSOME OF TODAY'S TOP BULLISH ACTIVITY IN $Z $AXTA $DIS $MDXG $ALKS $TNDM $VIPS..
5
09/20$AGN REPEAT OPENING BULL BET, NOV CALLS
1
More tweets
Qtime:241
News from SeekingAlpha
09/18Allergan Snaps Up Early Stage Startup, Goes Back To Its Aesthetic Roots 
09/18YOUR DAILY PHARMA SCOOP : Alnylam Regains, Karyopharm Positive, Teva Approved 
09/18Senate passes opioid crisis bill 
09/17House nixes drug prices in TV ads 
09/14Allergan's Botox shows treatment benefit at higher doses 
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 212 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Charles Hugh-Jones Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC14.95%63 826
JOHNSON & JOHNSON0.53%376 820
PFIZER19.44%253 595
NOVARTIS-0.56%216 184
ROCHE HOLDING LTD.-4.65%211 637
MERCK AND COMPANY25.79%186 114